Prognostic value of FGF23 among patients with end-stage renal disease: a systematic review and meta-analysis. (May 2016)

• Record Type: Journal Article
• Authors: Yang, Hongliu; Luo, Han; Tang, Xi; Zeng, Xiaoxi; Yu, Yang; Ma, Liang; Fu, Ping
• Is Part Of: Biomarkers in medicine. Volume 10:Number 5(2016)
• Page Start: 547
• Page End: 556
• Publication Date: 2016-05
• Subjects: dialysis -- end-stage renal disease -- FGF23 -- mortality; Biochemical markers -- Periodicals; 610.28
• DOI: 10.2217/bmm.16.11
• Languages: English
• ISSNs: 1752-0363

Abstract

Aims: Prognostic value of FGF23 in end-stage renal disease (ESRD) patients is controversial. A systematic review was conducted to quantify the association between elevated FGF23 and overall mortality among ESRD patients.Methods: MEDLINE, EMBASE, PubMed and reference lists were searched. Quality of the included studies was evaluated using Newcastle–Ottawa Scale checklist. Pooled effects were calculated as hazard ratio using fixed-effect models, and chi-square test was used for heterogeneity testing.Results: Seven studies (1406 patients) were included. Patients were at mean age of 62.3. Mean follow-up was 29.4 months. From the pooled analysis, elevated FGF23 was significantly associated with increased all-cause mortality (hazard ratio: 1.53; 95% CI: 1.05–2.25). p-value for heterogeneity was 0.10, I 2 = 48%.Conclusions: ESRD patients with elevated FGF23 concentration have higher risk of death.